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On two sunny days in Rome in November 2014, more
than 200 people with an interest in core outcome sets
(COS) from around the world gathered at The Pontificia
Università Lateranense for the fourth meeting of the
COMET Initiative. They came from 14 countries:
Austria, Canada, Denmark, France, Germany, Ireland,
Italy, Netherlands, Poland, Portugal, Romania, Switzerland,
UK and USA. The programme was introduced by Liz
Gargon (COMET Project Coordinator) and a summary of
the coming days was provided by the chair of the COMET
Management Group (Paula Williamson). Paula also pre-
sented the COMET strategic plan and provided a general
update and progress report since the last meeting in
Manchester in June 2013. Over the two days, the invited
plenary talks were complemented by three workshops, 52
posters (50% more than the number at the 2013 meeting)
and four contributed presentations.
On 19th November, Roberto D’Amico (University of
Modena) talked about the need for core outcome sets to
improve evidence synthesis, and Silvio Garattini (IRCCS-
Istituto di Ricerche farmacologiche Mario Negri) followed
him by discussing the use of surrogate and composite end-
points. He underlined the differences between core sets
and these end points and explained how the latter did not
always examine the outcomes most important to patients.
This became a prominent theme throughout the meeting
and was the focus of a dedicated session on 20th November
focussing on patient engagement and involvement in
COS development. A patient representative (Rosemary
Humphreys – HOME Initiative) emphasised why core out-
come sets are so important to patients, highlighting how
patients looking for information on their conditions on the
internet and elsewhere are confronted not only by the chal-
lenges of finding reliable information but, when they do,
they might find themselves looking at trials that did
not compare the same outcomes. She also stressed how
doctors might know about the condition, while patients
know about the impact. We also heard about the potential
challenges of public involvement from the perspective of a
COS developer (Iain Bruce, Royal Manchester Children’s
Hospital). Iain spoke about the practical, but essential,
aspects of arranging face to face meetings and ensuring
comprehensive involvement from all sections of a patient
group or society, including ‘hard to reach’ groups. Heather
Bagley, COMET Patient and Public Involvement (PPI)
coordinator, concluded this session with a presentation on
‘Involving people and the COMET PPI strategy’, which
outlines COMET’s public involvement objectives and
initial plans for public involvement activities. This report is
available at http://www.comet-initiative.org/resources/
publicinvolvement.
In a session designed to turn the generalities of develop-
ing COS, into the specifics of individual projects, we also
heard from three COS developers (Christian Apfelbacher,
University of Regensburg; Finn Gottrup, Copenhagen
Wound Healing Center, Bispebjerg University Hospital,
and Alessandro Chiarotto, VU University) about the meth-
ods used and their experiences of developing COS. Discus-
sion included the importance of defining the scope of the
COS from the outset and thinking about implementation
early on in the process. This provided the foundation for
later sessions, including one on COS development metho-
dology (Sara Brookes, University of Bristol, and Sanna
Prinsen, VU University). We also learned more about the
relevance of COS to systematic reviews, in particular
Cochrane Reviews. Holger Schünemann (McMaster
University) highlighted the links to the GRADE summary
of findings tables, suggesting that COS can help reviewers
decide on the important outcomes to present in their
tables. Valerie Smith (Trinity College Dublin) presented a
survey of outcomes in Cochrane Reviews, emphasising
that consistency of reporting of outcomes across and
between Cochrane Review groups is a challenge and that
Cochrane needs to play its part by using COS in their
reviews to help overcome this. The example of pain as an
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outcome that cuts across many of these Groups was
explored further by David Tovey (Cochrane Library) and
Peter Tugwell (University of Ottawa). It was clear that
there is much to be done to help standardise the outcomes
across and between Cochrane Groups, and COS might be
a great starting point for this.
The final session focussed on the links between COS,
COMET and other groups, such as the European Medi-
cines Agency (Irmgard Eichler) and National Institutes
of Health (Jerry Sheehan), and showed the potential role
for COS in the development of regulatory guidelines.
Sean Tunis (Center for Medical Technology Policy)
reported on the first COMET network meeting in North
America, held earlier in the year, where many organisa-
tions including FDA, AHRQ, NIH and PCORI came
together to learn about the importance and relevance of
COS, and to think more about the role that each of
these organisations may play. Payers were highlighted as
being stakeholders that had not been mentioned much
through the meeting but were another group that might
have an important role to play in the development and
implementation of COS, due to the rising costs of
healthcare and the pressures on them to spend money
efficiently. Sean described how he will use COS and
refer to COMET in guidance papers developed by the
Green Park Collaborative. Perhaps the most importance
message from this session was that we need to find
ways to collaborate and add value to the work of these
other organisations. This was exemplified by Khalid
Khan (Barts and The London School of Medicine and
Dentistry) who described the CoRe Outcomes in
WomeN’s health (CROWN) Initiative, a consortium of
women’s health journals aiming to promote core out-
come sets in all areas of the specialty, which now has
around 70 different journals signed up and committed
to the initiative.
COMET IV provided a unique opportunity for stake-
holders from different environments to share their ideas
and progress, and engage in discussion and debate. Parti-
cipants shared their challenges, needs, solutions and
resolutions. The meeting brought together key scientists
and consumers responsible for developing and imple-
menting COS, including trialists, systematic reviewers,
health service users, clinical teams, journal editors, trial
funders, policy makers, trials registries and regulators.
There was resounding support for the COMET Initiative
and unanimous agreement that COS have a vital role to
play in the future of clinical trials and health research.
Since COMET IV, we have already had follow up contact
with people and groups from the meeting. One example
is the European Commission Initiative in Breast Cancer
(ECIBC), and we hope that our days in Rome will be the
catalyst for much successful and productive collaboration
in the future. It was clear from the enthusiasm and
dedication shown throughout COMET IV that there is a
continued commitment to COS development and
application.
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